Skip to main content
. 2018 Mar 21;11(2):138–143. doi: 10.1007/s12254-018-0389-x

Fig. 1.

Fig. 1

Pseudoprogression in 54-year-old man with non-small cell lung cancer receiving immune checkpoint inhibitor therapy. a Coronary fluorodeoxyglucose positron emission tomopraphy/computed tomography (18F-FDG-PET/CT) imaging obtained before therapy demonstrate 18F-FDG avid malignant tumor in the right lung. b 5 weeks after treatment initiation tumor size and FDG uptake increased. Therapy was continued and 6 weeks thereafter tumor size shrinkage and a reduced 18F-FDG uptake were observed (c)